Pharma

Your Article Summary

See Latest Articles

Abbott Expands XIENCE V USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Abbott, 08/14/09

Abbott announced the expansion of the company's XIENCE V USA post–approval study designed to evaluate the safety and effectiveness of the company's market–leading XIENCE V Everolimus Eluting Coronary Stent System in a real–world clinical setting out to five years. The expansion allows for more than 2,000 patients from the XIENCE V USA trial to be eligible to cross over into the landmark Dual Anti–Platelet Therapy Trial, an industry–wide collaboration with medical device and pharmaceutical companies.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09

 See all of Drug Trials